Drug Development Research publishes research papers and review-type articles covering all area within drug development: from target identification and validation and structure–activity relationship studies, through to post-market clinical reports.
Topics covered include but are not limited to medicinal and process chemistry, pharmacology, biotechnology and biopharmaceuticals, toxicology, drug delivery, formulation, pharmacokinetics, clinical trial reviews and post-approval/post-marketing evaluation. The journal also welcomes manuscripts on new compounds and technologies in all areas focused on human therapeutics, as well as global management, health care policy and strategy, and regulatory issues that involve drug discovery and development.
Each submission is categorized in to one of the following sub-sections of DDR:
Hit, Lead & Candidate Discovery
e.g., target identification and validation, drug design, SAR studies, lead identification and optimization, etc.
Preclinical Research & Development
e.g., in vitro and in vivo evaluation of pharmacodynamics, pharmacokinetics, ADME, safety, toxicology, formulation, drug delivery, etc.
Clinical Research
e.g., Phases I–III clinical trials, trial material manufacturing (process chemistry), quality control/assurance, etc.
Post-Market Research
e.g., Phase IV clinical trials, post-market safety monitoring, off-label investigations, etc.
Enabling Technologies
e.g., genomics, metabolomics, proteomics, etc.
Strategy, Management & Health Policy
e.g., drug pricing and access, health care provision, etc.
Articles are considered for publication based on the aforementioned scope and the quality of the science reported. Only articles reporting rigorously conducted research and offering advancement to the scientific literature will be considered.

EDITOR
David Gurwitz (Dept. Human Molecular Genetics & Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel; E-mail: gurwitz@post.tau.ac.il)
 
ASSOCIATE EDITORS
Steven Fletcher (University of Maryland, Baltimore, USA; E-mail: sfletcher@rx.umaryland.edu)
Nataša Karas Kuželički (University of Ljubljana, Slovenia; E-mail: natasa.karaskuzelicki@ffa.uni-lj.si)
Alessio Squassina (University of Cagliari, Italy; E-mail: squassina@unica.it)
 
 
EDITORIAL BOARD
Arvind K. Bansal (Nat'l Inst. Pharmaceutical Education & Research (NIPER), SAS Nagar, India)
 Juan M. Benito (Instituto de Investigaciones Químicas, CSIC - Universidad de Sevilla, Spain)
Sun Choi (Ewha Womans University, Seoul, South Korea)
Carmela Fimognari (University of Bologna, Bologna, Italy)
   Francisco J. Flores-Murrieta (Instituto Politecnico Nacional, Mexico City, Mexico)
   Vinicio Granados Soto (Departamento de Farmacobiologia, Cinvestav, Mexico City, Mexico)
   Tommaso Iannitti (Charles River Discovery Research Services Ltd., Somerset, UK)
 Manzoor  Koyakutty (Amrita Vishwavidyapeetham University, India)
 Rangasamy Jayakumar (Amrita Institute of Medical Sciences and Research Centre, India)
   Cheng-Hao Jin (HeiLongJiang BaYi Agricultural University, Daqing, China)
Rafael León Martínez (Universidad Autónoma de Madrid, Madrid, Spain)
Michael Marschler (Patient Safety & Risk Management Expert, Mannheim, Germany)
Elena Milanesi (Victor Babes National Institute of Pathology, Bucharest, Romania)
   Rubens Lima do Monte Neto (Fiocruz Minas, Belo Horizonte, Brazil)
Jessica Mwinyi (Uppsala University Biomedical Center, Uppsala, Sweden)
Ioannis Nikolakakis (Aristotle University of Thessaloniki, Thessaloniki, Greece)
Tanya Parish (Infectious Disease Research Institute, Seattle, WA, USA)
Vesna Pesic (University of Belgrade, Belgrade, Serbia)
Avi Raveh (Blavatnik Center for Drug Discovery, Tel-Aviv University, Tel-Aviv, Israel)
  Nermin Salah Ahmed (German University of Cairo, New Cairo City, Egypt) 
David Selwood (University College London, UK) - Editor: Chem. Biol. Drug Des.
   Subhabrata Sen (Shiv Nadar University, Gautam Budhnagar, India; SRM University - Amaravati, AP, India)
   Ashok Shakya (Al-Ahliyya Amman University, Amman, Jordan)
Jana Tchekalarova (Institute of Neurobiology, Bulgarian Academy of Sciences, Sofia, Bulgaria)
Nicole Teusch (Technische Hochschule Koeln, Leverkusen, Germany)
Sid Topiol (3D-2drug, LLC, Fair Lawn, NJ, USA)
Sophie Visvikis-Siest (INSERM, Lorraine, France)
Binghe Wang (Georgia State University, Atlanta, GA, USA) - Editor: Med. Res. Rev.
    In-Soo Yoon (Pusan National University, Busan, South Korea) 
 
 
EDITOR EMERITUS
Michael Williams (Dept. Biological Chemistry & Pharmacology, College of Medicine, Ohio State University, Columbus, OH, USA)